Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone

Cancer Treatment Reviews

Volumn 39, Issue 8, 2013, Pages 966-973

  Pia, Anna ^a   Vignani, Francesca ^a   Attard, Gerhardt ^b   Tucci, Marcello ^a   Bironzo, Paolo ^a   Scagliotti, Giorgio ^a   Arlt, Wiebke ^c   Terzolo, Massimo ^a   Berruti, Alfredo ^d  

^a SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Abiraterone acetato; ACTH; Mineralcorticoid excess; Prostate cancer; Steroid supplementation

Indexed keywords

ABIRATERONE; CANRENONE; CORTICOTROPIN; CORTISONE ACETATE; DEXAMETHASONE; EPLERENONE; FLUDROCORTISONE; HYDROCORTISONE; METHYLPREDNISOLONE; MINERALOCORTICOID; PREDNISOLONE; PREDNISONE; SPIRONOLACTONE; TRIAMCINOLONE;

ADRENAL INSUFFICIENCY; ERECTILE DYSFUNCTION; HUMAN; PROSPECTIVE STUDY; PROSTATE CANCER; REVIEW;

ABIRATERONE ACETATO; ACTH; MINERALCORTICOID EXCESS; PROSTATE CANCER; STEROID SUPPLEMENTATION;

ADRENOCORTICOTROPIC HORMONE; ANDROSTENOLS; HUMANS; MALE; MINERALOCORTICOID EXCESS SYNDROME, APPARENT; MINERALOCORTICOIDS; PROSTATIC NEOPLASMS;

EID: 84883559111     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.03.003     Document Type: Review

References (52)

1. Sonpavde G., Attard G., Bellmunt J., et al. The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature. Eur Urol 2011, 60(2):270-278.
2. Attard G., Reid A.H., Auchus R.J., et al. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab 2012, 97(2):507-516.
3. Krone N., Arlt W. Genetics of congenital adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab 2009, 23(2):181-192.
4. De Bono J.S., Logothetis C.J., Molina A., et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011, 364(21):1995-2005.
5. Ryan C.J., Smith M.R., De Bono J.S., et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013, 368:138-148.
6. Rescigno P., Buonerba C., Bellmunt J., et al. New perspectives in the therapy of castration resistant prostate cancer. Curr Drug Targets 2012, 13(13):1676-1686.
7. Gomez-Sanchez C.E., Warden M., Gomez-Sanchez M.T., et al. Diverse immunostaining patterns of mineralocorticoid receptor monoclonal antibodies. Steroids 2011, 76:1541-1545.
8. Hernandez-Diaz I., Giraldez T., Arnau M.R., et al. The mineralocorticoid receptor is a constitutive nuclear factor in cardiomyocytes due to hyperactive nuclear localization signals. Endocrinology 2010, 151(8):3888-3899.
9. Nguyen Dinh Cat A., Griol-Charhbili V., Loufrani L., et al. The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure. FASEB J 2010, 24(7):2454-2463.
10. Caprio M., Feve B., Claes A., et al. Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J 2007, 21:2185-2194.
11. Usher M.G., Duan S.Z., Ivaschenko C.Y., et al. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest 2010, 120(9):3350-3364.
12. Williams G.H. Cardiovascular benefits of aldosterone receptors antagonists: what about potassium?. Hypertension 2005, 46(2):265-266.
13. Keidar S., Kaplan M., Pavlotzky E., et al. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development - A possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 2004, 109:2213-2220.
14. Funder J.W. The nongenomic actions of aldosterone. Endocr Rev 2005, 26:313-321.
15. Rocha R., Rudolph A.E., Frierdich G.E., et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002, 283(5):H1802-H1810.
16. Blasi E.R., Rocha R., Rudolph A.E., et al. Aldosterone/sal induces renal inflammation and fibrosis in hypertensive rats. Kydney Int 2003, 63(5):1791-1800.
17. Milliez P., Girerd X., Plouin P.F., et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005, 45(8):1243-1248.
18. Reil J.C., Hohl M., Selejan S., et al. Aldosterone promotes atrial fibrillation. Eur Heart J 2012, 33(16):2098-2108.
19. Milliez P., Girerd X., Plouin P.F., Blacher J., Safar M.E., Mourad J.J. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005, 45:1243-1248.
20. Marzolla V., Armani A., Zennaro M.C., et al. The role of the mineralocorticoid receptor in adipocyte biology and fat metabolism. Mol Cell Endocrinol 2012, 350(2):281-288.
21. Attard G., Reid A.H., Yap T.A., et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008, 26(28):4563-4571.
22. Hahner S., Allolio B. Therapeutic management of adrenal insufficiency. Best Pract Res Clin Endocrinol Metab 2009, 23(2):167-179.
23. Debono M., Ross R.J., Newell-Price J. Inadequacies of glucocorticoid replacement and improvements by physiological circadian therapy. Eur J Endocrinol 2009, 160(5):719-729.
24. Debono M., Ghobadi C., Rostami-Hodjegan A., et al. Modified-release hydrocortisone to provide circadian cortisol profiles. J Clin Endocrinol Metab 2009, 94(5):1548-1554.
25. Alten R. Chronotherapy with modified-release prednisone in patients with rheumatoid arthritis. Expert Rev Clin Immunol 2012, 8(2):123-133.
26. McMurray J.J., Adamopoulos S., Anker S.D., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 2012, 33(14):1787-1847.
27. Funder J.W. Primary aldosteronism: are we missing the wood for the trees. Horm Metab Res 2012, 44(3):251-253.
28. Bomback A.S., Klemmer P.J. Interaction of aldosterone and extracellular volume in the pathogenesis of obesity-associated kidney disease: a narrative review. Am J Nephrol 2009, 30(2):140-146.
29. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996, 78(8):902-907. Rales Investigators.
30. Luthy I.A., Begin D.J., Labrie F. Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture. J Steroid Biochem 1988, 31(5):845-852.
31. Gorlitzer K., Moormann P., Pollow K., et al. Synthesis and reactions of 2-methylene-canrenone. Arch Pharmacol (Weinheim) 1995, 328(2):149-155.
32. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348(14):1309-1321.
33. Ravis W.R., Reid S., Sica D.A., et al. Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment. J Clin Pharmacol 2005, 45(7):810-821.
34. Richards J., Lim A.C., Hay C.W., et al. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res 2012, 72(9):2176-2182.
35. Attard G., Reid A.H., A'Hern R., et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009, 27(23):3742-3748.
36. Ryan C.J., Smith M.R., Fong L., et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010, 28(9):1481-1488.
37. Taplin M.E., Bubley G.J., Shuster T.D., et al. Mutation of the androgen-receptor gene in metastatic androgenindependent prostate cancer. N Engl J Med 1995, 332:1393-1398.
38. Quinkler M. Treatment of primary aldosteronism. Best Pract Res Clin Endocrinol Metab 2010, 24(6):923-932.
39. Dietz J.D., Du S., Bolten C.W., et al. A number of marketed dihydropyridine calcium channel blockers have mineralcorticoid receptor antagonist activity. Hypertension 2008, 51:742-748.
40. Saha C., Eckert G.J., Ambrosius W.T., et al. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 2005, 46:481-487.
41. Reid A.H., Attard G., Danila D.C., et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010, 28(9):1489-1495.
42. Bennett N.C., Hooper J.D., Lambie D., et al. Evidence for steroidogenic potential in human prostate cell lines and tissues. Am J Pathol 2012, 181(3):1078-1087.
43. Arlt W., Walker E.A., Draper N., et al. Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study. Lancet 2004, 363(9427):2128-2135.
44. Funder J.W., Carey R.M., Fardella C., et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008, 93(9):3266-3281.
45. Olson C.A., Crudo D.F. Pubertal delay, hypokalemia and hypertension caused by a rare form of congenital adrenal hyperplasia. J Pediatr Adolesc Gynecol 2011, 24:e29-e31.
46. Zhang L., Wang H., Hong T. Diagnosis and treatment of 17alpha-hydroxylase deficiency: a case report and literature review. Beijing Da Xue Xue Bao 2008, 40(2):221-222.
47. Li H., Hongyan Q., Guo H. 17-alpha-Hydroxylase deficiency: a case report with clinical and molecular analysis. Gynecol Endocrinol 2010, 26(7):521-523.
48. Taura K., Tashiro T., Fujimatsu S., et al. A case of 17 alpha-hydroxylase deficiency with male pseudohermaphroditism. Nihon Naibunpi Gakkai Zasshi 1980, 56(6):843-854.
49. Verma S., Vanryzin C., Sinaii N., et al. A pharmacokinetic and pharmacodynamic study of delayed- and extended-release hydrocortisone (Chronocort) vs. conventional hydrocortisone (Cortef) in the treatment of congenital adrenal hyperplasia. Clin Endocrinol (Oxford) 2010, 72(4):441-447.
50. Johannsson G., Bergthorsdottir R., Nilsson A.G., Lennernas H., Hedner T., Skrtic S. Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. Eur J Endocrinol 2009, 161(1):119-130.
51. Koetz K.R., Ventz M., Diederich S., et al. Bone mineral density is not significantly reduced in adult patients on low-dose glucocorticoid replacement therapy. J Clin Endocrinol Metab 2012, 97(1):85-92.
52. Løvås K., Gjesdal C.G., Christensen M., et al. Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone. Eur J Endocrinol 2009, 160(6):993-1002.